%0 Journal Article
%A Vogelgsang, Jonathan
%A Hansen, Niels
%A Stark, Melina
%A Wagner, Michael
%A Klafki, Hans
%A Morgado, Barbara Marcos
%A Jahn-Brodmann, Anke
%A Schott, Björn
%A Esselmann, Hermann
%A Bauer, Chris
%A Schuchhardt, Johannes
%A Kleineidam, Luca
%A Wolfsgruber, Steffen
%A Peters, Oliver
%A Schneider, Luisa-Sophie
%A Wang, Xiao
%A Menne, Felix
%A Priller, Josef
%A Spruth, Eike Jakob
%A Altenstein, Slawek
%A Lohse, Andrea
%A Schneider, Anja
%A Fliessbach, Klaus
%A Vogt, Ina
%A Bartels, Claudia
%A Jessen, Frank
%A Rostamzadeh, Ayda
%A Duezel, Emrah
%A Glanz, Wenzel
%A Incesoy, Enise
%A Butryn, Michaela
%A Buerger, Katharina
%A Janowitz, Daniel
%A Ewers, Michael
%A Perneczky, Robert
%A Rauchmann, Boris Stephan
%A Guersel, Selim
%A Teipel, Stefan
%A Kilimann, Ingo
%A Goerss, Doreen
%A Laske, Christoph
%A Munk, Matthias
%A Sanzenbacher, Carolin
%A Spottke, Annika
%A Roy-Kluth, Nina
%A Heneka, Michael
%A Brosseron, Frederic
%A Ramirez, Alfredo
%A Schmid, Matthias
%A Wiltfang, Jens
%T Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.
%J Alzheimer's and dementia
%V 20
%N 8
%@ 1552-5260
%C Hoboken, NJ
%I Wiley
%M DZNE-2024-01078
%P 5132 - 5142
%D 2024
%X Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline.We measured levels of amyloid beta (Aβ)X-40 and AβX-42 in immunoprecipitated eluates from the DELCODE cohort. Receiver-operating characteristic (ROC) curves, regression analyses, and Cox proportional hazard regression models were constructed to predict AP by Aβ42/40 classification in cerebrospinal fluid (CSF) and conversion to mild cognitive impairment (MCI) or dementia.We detected a significant correlation between AßX-42/X-40 in plasma and CSF (r = 0.473). Mixed-modeling analysis revealed a substantial prediction of AßX-42/X-40 with an area under the curve (AUC) of 0.81 for AP (sensitivity: 0.79, specificity: 0.74, positive predictive value [PPV]: 0.71, negative predictive value [NPV]: 0.81). In addition, lower AβX-42/X-40 ratios were associated with negative PACC5 slopes, suggesting cognitive decline.Our results suggest that assessing the plasma AβX-42/X-40 ratio via our semiautomated IP-IA is a promising biomarker when examining patients with early or preclinical AD.New plasma Aβ42/Aβ40 measurement using immunoprecipitation-immunoassay Plasma Aβ42/Aβ40 associated with longitudinal cognitive decline Promising biomarker to detect subjective cognitive decline at-risk for brain amyloid positivity.
%K Humans
%K Amyloid beta-Peptides: blood
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Alzheimer Disease: blood
%K Alzheimer Disease: diagnosis
%K Alzheimer Disease: cerebrospinal fluid
%K Cognitive Dysfunction: blood
%K Cognitive Dysfunction: cerebrospinal fluid
%K Cognitive Dysfunction: diagnosis
%K Male
%K Female
%K Aged
%K Biomarkers: blood
%K Biomarkers: cerebrospinal fluid
%K Peptide Fragments: blood
%K Peptide Fragments: cerebrospinal fluid
%K Middle Aged
%K ROC Curve
%K Immunoprecipitation
%K Disease Progression
%K Alzheimer's disease (Other)
%K MCI (Other)
%K amyloid beta (Other)
%K biomarker (Other)
%K dementia (Other)
%K plasma (Other)
%K Amyloid beta-Peptides (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%K amyloid beta-protein (1-42) (NLM Chemicals)
%K amyloid beta-protein (1-40) (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%2 pmc:PMC11350048
%$ pmid:38940303
%R 10.1002/alz.13909
%U https://pub.dzne.de/record/271866